Tahoe Therapeutics secured $30 million in new funding. This capital fuels the creation of a vast dataset for training AI models of human cells. Amplify Partners led the round.
The company plans to generate one billion single-cell datapoints, mapping one million drug-patient interactions. Moreover, this definitive dataset supports the discovery of new precision medicines.
Advancing AI Cell Models for Drug Discovery
Tahoe previously released Tahoe-100M, a gigascale perturbative single-cell dataset. This dataset became foundational for teams building virtual cell models. It has been downloaded nearly 100,000 times. Consequently, it led to promising therapeutic candidates.
This new dataset aims to significantly reduce clinical trial failure rates.
Furthermore, Tahoe advances its own therapeutic programs. The company will select a single partner, like Recursion Pharmaceuticals or Insitro, to access the forthcoming dataset. This collaboration aims to develop the first medicines powered by virtual cell models, accelerating drug discovery.
Founders Nima Alidoust, Johnny Yu, Hani Goodzari, and Kevan Shokat bring expertise in genomics and machine learning. Thus, their platform enables scalable, large-scale single-cell drug screening across diverse patient contexts, advancing AI cell models. The company's technology platform generates large-scale, perturbative single-cell datasets. Additionally, these enable a new generation of biological foundation models, further enhancing AI cell models.
